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ABSTRACT
Objectives We aimed to investigate demographic, 
lifestyle, socioeconomic and clinical risk factors for 
COVID-19, and compared them to risk factors for 
pneumonia and influenza in UK Biobank.
Design Cohort study.
Setting UK Biobank.
Participants 49–83 year olds (in 2020) from a general 
population study.
Main outcome measures Confirmed COVID-19 infection 
(positive SARS- CoV-2 test). Incident influenza and 
pneumonia were obtained from primary care data. Poisson 
regression was used to study the association of exposure 
variables with outcomes.
Results Among 235 928 participants, 397 had confirmed 
COVID-19. After multivariable adjustment, modifiable risk 
factors were higher body mass index and higher glycated 
haemoglobin (HbA1C) (RR 1.28 and RR 1.14 per SD 
increase, respectively), smoking (RR 1.39), slow walking 
pace as a proxy for physical fitness (RR 1.53), and use of 
blood pressure medications as a proxy for hypertension 
(RR 1.33). Higher forced expiratory volume in 1 s (FEV1) 
and high- density lipoprotein (HDL) cholesterol were both 
associated with lower risk (RR 0.84 and RR 0.83 per 
SD increase, respectively). Non- modifiable risk factors 
included male sex (RR 1.72), black ethnicity (RR 2.00), 
socioeconomic deprivation (RR 1.17 per SD increase in 
Townsend Index), and high cystatin C (RR 1.13 per SD 
increase). The risk factors overlapped with pneumonia 
somewhat, less so for influenza. The associations with 
modifiable risk factors were generally stronger for 
COVID-19, than pneumonia or influenza.
Conclusion These findings suggest that modification of 
lifestyle may help to reduce the risk of COVID-19 and could 
be a useful adjunct to other interventions, such as social 
distancing and shielding of high risk.
INTRODUCTION
COVID-19, caused by SARS- CoV-2 infec-
tion, includes a spectrum of morbidity from 
asymptomatic infection1 to severe pneu-
monia in patients presenting for medical 
care.2 The COVID-19 pandemic3 has led to 
concerted research efforts to identify people 
at greatest risk of developing the infection 
and progressing to critical illness and dying. 
Predictors of disease severity include older 
age, smoking, diabetes, hypertension, kidney 
disease, chronic obstructive pulmonary 
disease (COPD) and previous cardiovascular 
disease (CVD).4–7 In addition, it is becoming 
clear that other risk factors might include 
obesity and low physical fitness.8 9 However, 
many studies investigate risk factors for 
disease progression to death or critical illness 
among hospitalised patients7 as opposed to 
healthy comparators.
Identifying the risk factors for COVID-19 is 
important in terms of identifying factors that 
can be modified to reduce risk, as well as iden-
tifying non- modifiable risk factors that can 
help identify high risk groups who require 
Strengths and limitations of this study
 ► Large cohort from a general population, as opposed 
to a cohort of hospitalised patients, at an age rele-
vant to more severe COVID-19 symptoms.
 ► Biochemistry assays performed in a single dedicat-
ed central laboratory.
 ► Extensively emerging and novel risk factors for 
COVID-19.
 ► UK Biobank is not representative of the whole UK 
population.
 ► Exposures were measured several years before the 
development of the outcomes, and misclassification 
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shielding and targeting for testing, and eventual vaccine 
and anti- viral therapies. Pneumonia is a life- threatening 
complication of COVID-19 infection.10 Established major 
risk factors for community- acquired pneumonia include 
many of the emerging risk factors for COVID-19.11 As 
COVID-19 is caused by SARS- CoV-2 viral infection, it may 
have risk factors for contraction of the disease that are 
common to other respiratory virus conditions such as 
Influenza.
UK Biobank is a large prospective, deeply phenotyped, 
population- based cohort study carried out in the UK.12 
Over the study period, testing for COVID-19 in England 
was conducted in accident and emergency (A&E) depart-
ments and in- hospital. These data were provided by 
Public Health England (PHE) and linked to UK Biobank 
baseline data. We aimed to establish modifiable and non- 
modifiable risk factors for confirmed COVID-19. We also 
aimed to compare these risk factors to risk factors for the 
incident pneumonia over a similar time span.
METHODS
Participants
UK Biobank was conducted via 22 assessment centres 
across England, Scotland and Wales between March 2006 
and December 2010 and recruited 502 624 participants 
aged 37–73 years. The present study was restricted to 
participants living in England for whom COVID-19 test 
results were available. Death data were available to the 
end of January 2018 in England. To reduce competing 
risks, whereby risk factors may influence risk of death 
before the pandemic occurred, we excluded from the 
study all participants known to have died prior to the 
COVID-19 pandemic. Baseline biological measurements 
were recorded and touch- screen questionnaires were 
administered according to a standardised protocol.12 13
Outcomes
Results of COVID-19 PCR tests for UK Biobank partici-
pants were provided by PHE.7 14 Data provided by PHE 
included the specimen date, specimen type (eg, upper 
respiratory tract), laboratory, origin (whether evidence 
from microbiological record that the was conducted in 
hospital setting or not) and result (positive or negative). 
At the time the manuscript was developed,15 data were 
available for the period 16 March 2020 to 3 May 2020. 
Results were available for 5356 tests conducted on 3003 
individuals. Confirmed COVID-19 infection (primary 
outcome) was defined as at least one positive result in 
the context of an in- hospital or A&E test. Any positive test 
result was used as a sensitivity analysis. Longer follow- up 
of the UK Biobank cohort has become available, but in 
this analysis, we have elected to investigate risk factors for 
more severe disease (in- hospital positive tests) in the early 
stages of the pandemic.
Pneumonia was defined based on the 10th revision 
of the International Classification of Diseases, (ICD-10) 
codes J12–J18, and influenza based on J09–J11, converted 
into Read Codes using the UK Biobank’s look- up table. 
Incident pneumonia and influenza, occurring after 1 
January 2016 (an arbitrary date taken to mimic the time 
lag from baseline exposure measurement to incident 
COVID-19 infection, while also obtaining sufficient case 
numbers) was obtained from a 41% sample of partici-
pants with available data from primary care. A sensitivity 
analysis was conducted using cases after 1 January 2015 
and demonstrated consistent data. An analysis was also 
conducted exploring risk factors for all cases of pneu-
monia and influenza after baseline.
Exposures
Exposures were measured at the baseline assessment 
visit between 2006 and 2010. ‘Modifiable’ risk factors 
were considered to include smoking, anthropometric 
measurements, glycated haemoglobin (HbA1C), lung 
function measurements, hypertension, high- density lipo-
protein (HDL) cholesterol, other lipid measurements, 
and measures of physical activity.
Current age (on 1 March 2020) was derived from 
the assessment date and age at recruitment. Ethnicity, 
smoking, alcohol consumption, physician- diagnosed 
prevalent conditions and medication use were self- 
reported. For the present analyses, ethnicity was coded as 
white, south Asian, black, or mixed/other. Smoking status 
was categorised into never vs former/current smoking. 
Systolic and diastolic blood pressures were measured 
at the baseline visit, preferentially using an automated 
measurement, but using manual measurement where 
this was not available, and average of available measures 
used. Area- level socioeconomic deprivation was assessed 
by the Townsend score (incorporating measures of unem-
ployment, non- car ownership, non- home ownership and 
household overcrowding) corresponding to the partici-
pants’ home postcode. Higher scores on the Townsend 
score represent greater socioeconomic deprivation. Self- 
reported walking pace was rated by each participant as 
slow, steady/average, or brisk.16
The definition of baseline diabetes included self- 
reported type 1 or type 2 diabetes, those with a primary 
or secondary hospital diagnoses relating to diabetes 
at baseline (ICD-10 codes E10- E14.9), and those who 
reported using diabetes medications. Baseline CVD was 
defined as self- reported myocardial infarction, stroke, or 
transient ischaemic attack. Cancer, longstanding illness, 
and depression were self- reported on touchscreen ques-
tionnaire. Other previous health complaints including 
asthma, rheumatoid arthritis, chronic kidney disease, 
systemic lupus erythematosus, sleep apnoea, COPD, 
pneumonia, bronchitis (including bronchitis, bronchi-
ectasis and emphysema), and other respiratory diseases 
(including interstitial lung disease, asbestosis, pulmonary 
fibrosis, alveolitis, respiratory failure, pleurisy, pneumo-
thorax, other respiratory condition) which were derived 
from self- report at nurse interview. Some conditions were 
not included in multivariable analysis due to low case 
numbers and/or high correlations with other conditions, 
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but univariable results are presented for completeness. 
Statin (categorised to include other cholesterol lowering 
medications) and blood pressure medication use were 
also recorded from self- report, with blood pressure 
medication being used as a proxy for baseline diagnosed 
hypertension.
Body mass index (BMI) is the ratio of the measured 
body mass in kg divided by height squared measured in 
metres. Height was measured using a Seca 202 height 
measure. Weight and whole- body fat mass and fat free 
mass were measured to the nearest 0.1kg using the Tanita 
BC-418 MA body composition analyser. Socks and shoes 
were removed when height was measured Grip strength 
was measured using a Jamar J00105 hydraulic hand dyna-
mometer and the mean was derived from the right and 
left hand values expressed in kilograms.17
Lung function was assessed by spirometry using a Vitalo-
graph Pneumotrac 6800 spirometer (Vitalograph, Buck-
ingham, UK). Participants did not perform spirometry if 
they answered yes to unsure to the following: chest infec-
tion in the last month, history of detached retina, heart 
attack, surgery to eyes, chest or abdomen in last 3months, 
history of collapsed lung, pregnancy, or currently on 
medication for tuberculosis. The aim was to record two 
acceptable blows from a maximum of three attempts. The 
spirometer software compared the acceptability of the 
first two blows and, if acceptable (defined as a ≤5% differ-
ence in forced vital capacity (FVC) and forced expiratory 
volume in 1 s (FEV1)), the third blow was not required. 
The mean observation was taken for both measures.
Blood collection sampling procedures for the study 
have been previously described and validated.18 Biochem-
ical assays were performed at a dedicated central labo-
ratory on around 480 000 samples. Further details of 
these measurements can be found in the UK Biobank 
Data Showcase and Protocol (http://www. ukbiobank. ac. 
uk). For the present study we included total cholesterol, 
HDL cholesterol, rheumatoid factor, cystatin C, HbA1C, 
C reactive protein (CRP), differential white cell count 
and red cell distribution width as exposures of interest. 
Biomarkers with data below the limit of detection were 
imputed as the square root of the limit of detection. The 
majority of participants had undetectable rheumatoid 
factor and risk ratios were derived for detectable rheuma-
toid factor, with the referent being undetectable.
Statistics
Mean and SD were reported for continuous outcomes 
except for biomarkers, where median and IQR were 
reported. Poisson regression with robust ‘sandwich’ stan-
dard errors were used to study the associations of expo-
sure variables with confirmed COVID-19 and pneumonia. 
Poisson regressions were used because they provide risk 
ratio (RR) which is easier to interpret and robust error 
estimation ensures accurate inference.19 Three adjust-
ment schemes were considered: model 0—univariate (ie, 
no adjustment), model 1—adjusted for age, sex, ethnicity 
and deprivation index, and model 2—further adjusted for 
behavioural (smoking and alcohol drinking) and physical 
(adiposity, blood pressure, spirometry and physical capa-
bility) factors that were found to be significant in model 
1. In model 2, there were variables that were derived from 
the same variable (eg, BMI and BMI categories) and have 
strong correlations (r=0.87 between BMI, and body fat 
mass, and r=0.97 between FEV1 and FVC). To avoid multi-
collinearity, in model 2, we chose one from, BMI, BMI 
categories, body fat- free mass, body fat mass and body fat 
per cent. and one from FEV1, FVC and FEV1/FVC. For 
continuous variables, the linearity of exposure- outcome 
associations were tested using penalised cubic splines 
in generalised additive model.20 Nonlinearity was tested 
using likelihood ratio test comparing a model with the 
exposure fitted on a spline with a model assuming a linear 
exposure- outcome relationship. P value for nonlinearity 
<0.05 suggest evidence against the linearity assumption. 
Spline smoothness was chosen using generalised cross 
validation.21 Population attributable fractions (PAFs) 
were calculated to determine the relative contribution 
of each risk factor to the overall number of confirmed 
COVID-19 cases within UK Biobank. Another Poisson 
model which included all significant factors in model 2 
was fitted to estimate the mutually adjusted risk ratios 
(RRs). These RRs were biased towards null because of 
over adjustment bias but were used to construct the PAFs 
to ensure the PAF estimates did not overlap or exceed 
100%. In general, two- tailed p values<0.05 were consid-
ered statistically significant. Analyses were conducted in R 
Statistical Software V.3.5.3 with the package ‘mgcv’.
Patient and public involvement
UK Biobank maintains a website and twitter feed to keep 
participants, the general public and researchers up to 
date on the study (http://www. ukbiobank. ac. uk/ news/). 
There is an annual scientific meeting which is recorded 
and available to the public as webcast. The results of the 
present study are shared through these channels as the 
UK Biobank organisation deem appropriate, our own 
twitter feeds and open- access publication.
The study was set up by the MRC, Department of Health 
and Wellcome Trust with input from major patient repre-
sentative organisations (British Heart Foundation and 
Cancer Research UK: http://www. ukbiobank. ac. uk/ 
public- consultation/).
RESULTS
Of 445 857 participants in England, 428 225 were alive 
during the available follow- up period. Complete data 
on covariates were available for 235 928 (55.1%) partic-
ipants. Primary care data on incident pneumonia were 
available in 96 814 (41.0%) participants (online supple-
mental figure 1). At 1 March 2020, the age range of 
eligible participants was 49–83 years, and time elapsed 
from baseline was median 10.97 years (IQR 10.36–11.55 
years). Of these participants, 1525 received at least one 
COVID-19 test, and 518 had confirmed SARS- CoV-2 
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infection, with 397 positive results conducted in hospital 
or A&E (primary outcome).
Univariable risk factors for incident COVID-19
Key univariable potentially modifiable risk factors for 
confirmed COVID-19 included current and former 
smoking (RR 1.56), higher BMI, body fat and HbA1C (RR 
2.32 for obesity), poor lung function (RR 0.84 for 1 SD 
increase in FEV1), treated hypertension (RR 1.89), HDL 
cholesterol (RR 0.71 per SD increase) and slow walking 
pace (RR 2.29; table 1). Among non- modifiable risk 
factors were older age (particularly the over 75 year olds; 
RR 1.44), male sex (RR 1.38), black ethnicity (RR 2.88), 
socioeconomic deprivation (RR 1.30 per SD increase 
in Townsend Index; table 1). Among baseline comor-
bidities, general long standing illness (RR 1.59), base-
line diabetes (RR 2.16), baseline CVD (RR 1.93), sleep 
apnoea (RR 3.32), statin use (RR 1.80), higher inflamma-
tory markers (particularly white blood cell count; RR 1.17 
per SD increase) and higher cystatin C (RR 1.34 per SD 
increase) were also associated with confirmed COVID-19 
(table 1). Risk factor associations were similar when all 
518 test positive COVID-19 cases were considered, rather 
than only in- hospital positive tests (online supplemental 
table 1).
Univariable risk factors for incident pneumonia
Of the 96 814 participants with primary care data, 209 had 
pneumonia recorded after 2016.
Of the modifiable risk factors, pneumonia was associ-
ated with BMI, body fat and HbA1C (more moderately 
than COVID-19; RR 1.43 for obesity), poor lung function 
(more strongly than COVID-19; RR 0.63 for 1 SD increase 
in FEV1), and slow walking pace (RR 2.07), but not 
smoking, lipids, blood pressure or blood pressure medi-
cation use. Among non- modifiable risk factors, incident 
pneumonia was more common in participants who were 
older (RR 2.09 in the over 75 year olds), and in women 
(RR 0.59 among men) (table 1). Ethnicity was not asso-
ciated with pneumonia. Among comorbidities, baseline 
diabetes, CVD and cancer were approximately twice as 
common in those who developed pneumonia (table 1), 
and any longstanding illness was also associated with 
pneumonia. Inflammatory markers were similarly associ-
ated with pneumonia as with COVID-19.
When investigating risk factors for pneumonia over 
the full follow- up time from baseline, risk factors were 
generally similar although there was increased power 
due to a higher number of incident cases (online supple-
mental table 1). In this analysis, smoking was associated 
with pneumonia (RR 1.15) as was blood pressure medica-
tion use (RR 1.13). Similar findings were found when we 
studied pneumonia occurring after 2015 (online supple-
mental table 22).
Univariable risk factors for incident influenza
Of the 96 814 participants with primary care data, 94 had 
influenza recorded after 2016.
Those who developed influenza were generally slightly 
more socioeconomically deprived (RR 1.20 per SD 
increase in Townsend score), more likely to have bron-
chitis at baseline, and less likely to take statins. No other 
risk factors showed associations (table 1). When all influ-
enza cases occurring after baseline were considered, 
evidence of statistically significant associations emerged 
due to increased power. Smoking (RR 1.18), poor lung 
function (RR 0.84 for 1 SD increase in FEV), slow walking 
pace (RR1.35), and high BMI (RR 1.20 for obesity) were 
all associated with higher influenza risk (online supple-
mental table 1). Cases were less common in older people 
(RR 0.69 in the over 75 year olds) and more common in 
women (RR 0.83 in men). South Asians (RR 2.20) were at 
increased risk.
Multivariable models for COVID-19 and pneumonia
After multivariable adjustment for age, sex, ethnicity 
and socioeconomic status, the modifiable risk factors for 
confirmed COVID-19 included smoking (RR 1.45 (95% 
CI 1.19 to 1.79)), higher BMI (RR 1.36 per SD increase 
(95% CI 1.25 to 1.48)) and other measures of body fat, 
higher HbA1C (RR 1.23 per 1 SD increase (95% CI 1.15 
to 1.32)), as well as blood pressure medication, FEV1 and 
FVC, and slow walking pace (RR 1.99 (95% CI 1.48 to 
2.68); model 1, table 2). Other risk factors were older 
age (RR 1.12 per 5 years (95% CI 1.05 to 1.19)), male sex 
(RR 1.36 (95% CI 1.11 to 1.66)), black ethnicity (RR 2.32 
(95% CI 1.33 to 4.04)), South Asian ethnicity (RR 1.98 
(95% CI 1.10 to 3.55)) socioeconomic deprivation (RR 
1.27 per SD increase in Townsend Index (95% CI 1.16 to 
1.39)). Among comorbidities, risk factors included long-
standing illness (RR 1.44 (95% CI 1.17 to 1.77)), diabetes, 
CVD and statin use. Among blood biomarkers, risk factors 
included lower total and HDL cholesterol, higher cystatin 
C (RR 1.27 per 1 SD increase (95% CI 1.16 to 1.39)), CRP 
and white cell count (table 2).
After adding BMI, blood pressure, FEV1 and walking 
pace as mediators/covariates to the adjustment model, 
modifiable risk factors for COVID-19 admission continued 
to include smoking (RR 1.39 (95% CI 1.13 to 1.73)), 
higher BMI (RR 1.28 (95% CI 1.16 to 1.40)), higher 
HbA1C (RR 1.14 (95% CI 1.05 to 1.23), treated hyperten-
sion (RR 1.33 95% CI 1.04 to 1.70) and slow walking pace 
(RR 1.53 (95% CI 1.12 to 2.08)). The age association was 
no longer significant after these additional adjustments. 
Other risk factors included male sex (RR 1.72 (95% CI 
1.25 to 2.35)), black ethnicity (RR 2.00 (95% CI 1.16 to 
3.53)), socioeconomic deprivation (RR 1.17 (95% CI 1.06 
to 1.29)), lower HDL cholesterol (RR 0.83 (95% CI 0.73 
to 0.95)) and higher cystatin C (RR 1.13 (95% CI 1.02 to 
1.25); model 2, table 2).
Nonlinear associations of continuous variables with 
COVID-19 and pneumonia are shown in figure 1 (,and 
online supplemental table 3). Age was associated with 
COVID-19 admission in a J- shaped curve, where for 
participants aged 60–70 years the curve was relatively flat, 
and for participants aged over 75 years risk increased 
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exponentially with age. The associations of BMI and 
FEV1 with COVID-19 were fairly linear. Associations were 
similar when adjusting for body fat percentage rather 
than BMI (online supplemental table 4).
Directly contrasting model 2 for COVID-19 and pneu-
monia (figure 2), the risk factors in common for both 
conditions were higher BMI and slow walking pace, 
although less strongly associated with pneumonia than 
for COVID-19. Highlighting specific differences, smoking 
and treated blood pressure were only associated with 
COVID-19. Pneumonia was more common in women, and 
socioeconomic deprivation, HDL cholesterol, cystatin C 
and HbA1c were not associated with pneumonia. Low 
FEV1 was more strongly associated with pneumonia than 
with COVID-19. Pneumonia also showed an association 
with baseline cancer.
Population attributable risks
Factors that were significant in table 2 were mutu-
ally adjusted to compare their PAFs for COVID-19 and 
pneumonia (table 3). Among potentially modifiable risk 
factors smoking accounted for 14.9% of COVID-19 cases 
that occurred within the UK Biobank population, obesity 
with 6.3%, high HbA1C with 5.3%, treated BP with 
5.1%, and slow walking pace with 4.0% (total 35.6%). In 
contrast, none of these factors were large contributors to 
pneumonia cases within UK Biobank (table 3).
DISCUSSION
In this population- based study, we found that confirmed 
COVID-19 infection was associated with a number of modi-
fiable risk factors, a trend that less apparent for pneumonia 
and influenza. In particular, the associations of smoking, 
BMI (and body fat), hypertension and physical fitness (as 
measured by slow walking pace) with COVID-19 are of 
note; even when such factors were measured a decade 
before infection they potentially accounted for one- third 
of COVID-19 cases in UK Biobank. The associations of 
FEV1 and BMI with COVID-19 are linear, suggesting even 
modest improvements in lifestyle may be beneficial to risk 
of presumed severe COVID-19 symptoms. The other inde-
pendent risk factors for COVID-19 infection included 
older age, male sex, black ethnicity, socioeconomic depri-
vation, longstanding illness and reduced renal function 
as measured by cystatin C, the latter also notable given 
renal complication in severe COVID-19. Of note, the 
modifiable risk factors explained some of the association 
of age with COVID-19 in our adjusted model.
Since this analysis was conducted,15 several other studies 
have also shown the association between modifiable 
and non- modifiable risk factors and COVID-19 risk,22–29 
particularly with obesity. Generally, these data support 
our analyses showing the importance of both modifi-
able and non- modifiable risk factors. It is important to 
recognise the competing risk for health of lockdown and 
social distancing. Social distancing reduces viral trans-
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data suggest that physical fitness can be rapidly lost when 
activity levels decrease,30 31 and this will also result in 
an increase in BMI.32 33 Further, social distancing may 
increase loneliness, depression and psychological stress 
in some people and consequently adversely affect eating 
habits34 and other health behaviours. Anecdotal evidence 
from our clinics and media suggest many are strug-
gling with overeating. This study suggests public health 
guidance should focus on reducing the risk of severe 
complications of COVID-19 by advocating a healthy life-
style during the ongoing pandemic, not just for general 
cardiovascular and metabolic health, but also to help to 
protect against COVID-19 infection, used alongside other 
public health interventions.
Understanding the actual causes of disease, rather than 
markers that simply correlate with exposures, is clearly 
a key issue to consider. The independent association of 
socioeconomic deprivation with COVID-19 after multiple 
adjustment may be explained by the accumulation of 
earlier life socioeconomic adversities which can result in 
less physiological reserve and more multimorbidity.34 35 It 
may also be linked to more overcrowding, reduced social 
distancing and potential exposure to greater viral load. 
Asthma, diabetes and high blood pressure, which have 
been shown to be associated with a higher risk of severe 
COVID-19 outcomes36 also showed some trends to be 
associated with COVID-19 in this dataset. While substan-
tial focus of COVID-19 research has been its apparently 
more aggressive symptoms and disease progression in 
older people, it is important to recognise that people who 
are older have less cardiorespiratory reserve to cope with 
COVID-19 infection. Older age is also associated with 
more hypertension and diabetes, poorer lung function 
and greater relative fat mass.34
Previous reports have suggested that obesity or excess 
ectopic fat deposition may be a unifying risk factor for 
severe COVID-19 infection,8 37 reducing both protec-
tive cardiorespiratory reserve as well as potentiating the 
immune dysregulation that appears, at least in part, to 
mediate the progression to critical illness in a propor-
tion of patients with COVID-19. Our analysis bears out 
these hypotheses. Once BMI or body fat was adjusted for, 
inflammatory markers were no longer associated with 
incident COVID-19. This suggests that proinflammatory 
markers, arising from increased adipose deposition, are 
probably acting as a marker for body fat which seems to be 
an adverse risk factor for severe COVID-19.8 37–39 Further-
more, obesity enhances thrombosis,40 which is relevant 
given the association between severe COVID-19 and 
prothrombotic disseminated intravascular coagulation 
and high rates of venous thromboembolism,41 42 as well 
as the association with D- dimer seen in other reports.43 
D- dimer was not measured in blood samples in UK 
Biobank.
Given that pneumonia is a critical clinical complica-
tion of COVID-19, it is important to understand how risk 
Figure 1 Non- linear associations of significant continuous variables with COVID-19 and pneumonia. BMI, bodty mass index; 
FEV1, forced expiratory volume in one second.
Figure 2 Risk factors for COVID-19 and pneumonia in the UK Biobank cohort. Data presented as risk ratios (RR) and their 
95% CI. Analyses were adjusted for age, sex, ethnicity, deprivation, body mass index (BMI), forced expiratory volume in 
1 s (FEV1) and walking pace (and diastolic blood pressure for COVID-19 only). Continuous exposures were standardised 
and presented per 1- SD increment (deprivation index SD=3.01, cystatin C SD=0.14, BMI SD=4.59, HbA1c SD=5.80, FEV1 
SD=0.77 and HDL cholesterol SD=0.37). BP, blood pressure.
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factors for COVID-19 related pneumonia differ from 
‘classic’ community acquired pneumonia.11 Our compar-
ison between other common respiratory diseases and 
COVID-19 suggests that identification of at- risk groups 
based on our understanding of other respiratory diseases 
may be inadequate—a more refined approach to risk 
stratification based on COVID-19 specific risks is needed, 
and future data should focus on some of the exposures we 
identify to achieve this.
The strengths of our study include the large cohort size 
at an age relevant to more severe COVID-19 symptoms, 
and biochemistry assays performed in a single dedicated 
central laboratory. We were also able to extensively 
explore emerging and novel risk factors for COVID-
19, while simultaneously comparing to risk factors for 
pneumonia identified to primary care providers. Limita-
tions include that UK Biobank is not representative of 
the whole UK population44 (our data focus on England 
specifically) although this is generally not a concern 
in investigating risk associations.45 Care should be 
taken in generalising the PAF estimates. These related 
to cases occurring within the UK Biobank population, 
but are not directly applicable to the general popula-
tion where the prevalence of risk factors is different. In 
addition, mutual adjustment for overlapping risk factors 
can lead to problems in interpretability of the PAFs.46 
However, the direction of causal associations with this 
new outcome is not clear, and these exploratory anal-
yses allow a direct comparison between COVID-19 and 
pneumonia in the same cohort. Due to the under- 
representation of non- white ethnicities in UK Biobank, 
we have limited power to explore important interactions 
by ethnic group (although black ethnicity was associated 
with the outcome), and we recognise this as an important 
risk factor. Ascertainment bias, including differential 
healthcare seeking, differential testing and differential 
prognosis may explain some differences in outcomes 
given poor coverage of testing in the UK. It is also likely 
that cases will generally be at the more severe end of 
the clinical spectrum by using hospitalised cases as the 
outcome, although use of admission to Intensive Care 
units would be additionally informative once sufficient 
case numbers accrue. Despite this, we still observe many 
similar risk factors to incident pneumonia, which is more 
likely to have close to complete case ascertainment in 
primary care records, although, as discussed, other risk 
factors seem more strongly linked to COVID-19 infec-
tions. Exposures were measured several years before 
the development of the outcomes, and misclassification 
of the exposures will likely bias our results to the null. 
However, this also serves to illustrate that the risk factors 
were generally present many years before development 
of the disease, and as is well known, risk factors tend to 
track with age. We have also been unable to fully exclude 
all deaths that occurred prior to the pandemic, due to 
lack of up- to- date linkage to mortality records.
In conclusion, these data from UK Biobank suggest risk 
factors for confirmed COVID-19 infection differ in some 
important ways from risk factors for pneumonia, being 
more common in men than women, in lower SES, and 
with stronger associations with ethnicity, CV risk markers, 
prior smoking and adiposity. Such findings suggest 
possible merit in advocating improvements in lifestyle as 
an additional measure to reduce the risk of COVID-19 
alongside existing public health measures such as social 
distancing and shielding of high risk groups. They also 
Table 3 Population attributable fractions of COVID-19 in the UK Biobank
COVID-19 Pneumonia after 2016
RR (95% CI) PAF (%) RR (95% CI) PAF (%)
Current/former smoker 1.39 (1.13 to 1.70) 14.94 0.91 (0.69 to 1.20) −4.15
High deprivation index 1.45 (1.16 to 1.82) 8.33 1.00 (0.71 to 1.40) −0.10
Male 1.18 (0.94 to 1.50) 8.00 0.64 (0.46 to 0.90) −20.65
Age >65 years 1.18 (0.94 to 1.46) 6.33 1.29 (0.96 to 1.73) 9.88
BMI>30 kg/m2 1.29 (1.03 to 1.61) 6.25 1.14 (0.83 to 1.57) 3.17
High HbA1c 1.29 (1.02 to 1.62) 5.26 1.37 (1.00 to 1.88) 6.66
Low HDL cholesterol 1.27 (1.00 to 1.61) 5.15 1.34 (0.95 to 1.91) 6.45
BP medication 1.34 (1.05 to 1.71) 5.11 0.88 (0.60 to 1.29) −2.19
High cystatin C 1.24 (0.98 to 1.56) 4.48 1.12 (0.80 to 1.57) 2.39
Slow walking pace 1.66 (1.23 to 2.24) 4.02 1.78 (1.17 to 2.70) 4.69
Ethnicity: black 1.87 (1.32 to 2.65) 4.00 0.70 (0.34 to 1.45) −2.00
Low FEV1 1.15 (0.88 to 1.50) 2.93 1.64 (1.18 to 2.28) 11.23
Estimated using prevalence in the study sample and RR shown in this table.
All factors shown are mutually adjusted. Continuous variables were categorised with the top 20% as the at- risk group.
RR shown in this table may be over adjusted, for example, cystatin C and HDL cholesterol may be downstream factors of body mass index 
(BMI).
BP, blood pressure; FEV1, forced expiratory volume in 1 s.
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have implications for health advice targeted at the public 
to lessen risks during this pandemic.
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n=1362 RR* P 
Age (years) 66.53 (8.09) 67.04 (8.93) 1.07 0.15 66.51 (8.06) 67.24 (8.18) 1.09 < 0.0001 66.54 (8.06) 65.63 (8.17) 0.90 < 0.0001 
Age categories (years)                   
<60 58639 (24.91) 146 (28.19) 1 REF 23107 (24.58) 631 (22.54) 1 REF 23349 (24.46) 389 (28.56) 1 REF 
60-64 37569 (15.96) 62 (11.97) 0.66 0.007 14884 (15.83) 370 (13.22) 0.91 0.16 15027 (15.74) 227 (16.67) 0.91 0.25 
65-69 42802 (18.18) 68 (13.13) 0.64 0.002 17128 (18.22) 523 (18.69) 1.11 0.06 17392 (18.22) 259 (19.02) 0.90 0.17 
70-74 55711 (23.67) 108 (20.85) 0.78 0.049 22584 (24.02) 712 (25.44) 1.15 0.010 23000 (24.10) 296 (21.73) 0.78 0.0009 
≥75 40689 (17.28) 134 (25.87) 1.32 0.02 16312 (17.35) 563 (20.11) 1.26 < 0.0001 16684 (17.48) 191 (14.02) 0.69 < 0.0001 
Male sex, n (%) 111029 (47.16) 285 (55.02) 1.37 0.0004 44786 (47.64) 834 (29.80) 0.48 < 0.0001 45041 (47.19) 579 (42.51) 0.83 0.0006 
Ethnicity, n (%)                   
White 224116 (95.20) 455 (87.84) 1 REF 90008 (95.74) 2670 (95.39) 1 REF 91423 (95.78) 1255 (92.14) 1 REF 
Black 3045 (1.29) 26 (5.02) 4.18 < 0.0001 879 (0.93) 32 (1.14) 1.22 0.26 899 (0.94) 12 (0.88) 0.97 0.92 
South Asian 3502 (1.49) 18 (3.47) 2.52 0.0001 1546 (1.64) 62 (2.22) 1.34 0.02 1560 (1.63) 48 (3.52) 2.20 < 0.0001 
Others 4747 (2.02) 19 (3.67) 1.97 0.004 1582 (1.68) 35 (1.25) 0.75 0.09 1570 (1.64) 47 (3.45) 2.15 < 0.0001 
Deprivation index (score) -1.44 (2.98) -0.50 (3.39) 1.32 < 0.0001 -1.49 (2.89) -1.19 (3.07) 1.10 < 0.0001 -1.49 (2.89) -0.98 (3.16) 1.18 < 0.0001 
Current/former smoker, n (%) 106773 (45.36) 280 (54.05) 1.42 < 0.0001 42567 (45.28) 1369 (48.91) 1.15 0.0001 43261 (45.32) 675 (49.56) 1.18 0.002 
Alcohol drinking status, n (%)                   
Never 8885 (3.77) 36 (6.95) 1 REF 3573 (3.80) 154 (5.50) 1 REF 3668 (3.84) 59 (4.33) 1 REF 
Former 7464 (3.17) 24 (4.63) 0.79 0.38 2963 (3.15) 140 (5.00) 1.09 0.44 3045 (3.19) 58 (4.26) 1.18 0.37 
Current 219061 (93.06) 458 (88.42) 0.52 0.0001 87479 (93.05) 2505 (89.50) 0.67 < 0.0001 88739 (92.97) 1245 (91.41) 0.87 0.31 
BMI (kg/m2) 27.31 (4.56) 29.15 (5.29) 1.40 < 0.0001 27.40 (4.55) 27.88 (5.01) 1.10 < 0.0001 27.41 (4.56) 27.74 (4.81) 1.07 0.009 
BMI categories, n (%)                   
Underweight 787 (0.33) 1 (0.19) 0.87 0.89 295 (0.31) 11 (0.39) 1.29 0.40 306 (0.32) 0 (0.00) 0.00 0.92 
Normal 78044 (33.15) 114 (22.01) 1 REF 30371 (32.30) 873 (31.19) 1 REF 30821 (32.29) 423 (31.06) 1 REF 
Overweight 101703 (43.20) 220 (42.47) 1.48 0.0007 40839 (43.44) 1108 (39.59) 0.95 0.21 41388 (43.36) 559 (41.04) 0.98 0.80 
Obese 54876 (23.31) 183 (35.33) 2.28 < 0.0001 22510 (23.94) 807 (28.83) 1.24 < 0.0001 22937 (24.03) 380 (27.90) 1.20 0.008 
Body fat-free mass (Kg) 53.76 (11.47) 56.39 (11.55) 1.25 < 0.0001 53.84 (11.50) 50.54 (10.66) 0.74 < 0.0001 53.75 (11.50) 52.98 (11.20) 0.93 0.01 
Body fat mass (Kg) 24.49 (9.19) 27.48 (10.59) 1.32 < 0.0001 24.64 (9.19) 26.67 (9.89) 1.21 < 0.0001 24.69 (9.21) 25.47 (9.56) 1.08 0.002 
Body fat proportion (percent) 31.01 (8.40) 32.27 (8.56) 1.16 0.0007 31.11 (8.40) 34.05 (8.28) 1.40 < 0.0001 31.18 (8.41) 32.09 (8.32) 1.11 < 0.0001 
Systolic blood pressure (mmHg) 137.24 (18.07) 138.40 (18.89) 1.07 0.14 137.60 (18.11) 135.90 (17.67) 0.91 < 0.0001 137.59 (18.10) 135.00 (17.69) 0.86 < 0.0001 
Diastolic blood pressure (mmHg) 82.07 (9.90) 83.13 (10.49) 1.11 0.02 82.22 (9.90) 81.22 (9.60) 0.91 < 0.0001 82.20 (9.89) 81.31 (10.16) 0.91 0.0010 
FEV1 (litres) 2.86 (0.77) 2.75 (0.78) 0.86 0.0007 2.87 (0.78) 2.57 (0.73) 0.67 < 0.0001 2.86 (0.78) 2.73 (0.78) 0.84 < 0.0001 
FVC (litres) 3.79 (0.98) 3.68 (0.97) 0.89 0.01 3.80 (0.99) 3.44 (0.91) 0.68 < 0.0001 3.79 (0.99) 3.63 (0.96) 0.85 < 0.0001 
FEV1/FVC 0.76 (0.06) 0.75 (0.07) 0.88 0.002 0.76 (0.06) 0.75 (0.07) 0.89 < 0.0001 0.76 (0.06) 0.75 (0.07) 0.95 0.045 
Walking pace, n (%)                   
Slow 14872 (6.32) 74 (14.29) 2.15 < 0.0001 5895 (6.27) 324 (11.58) 1.74 < 0.0001 6098 (6.39) 121 (8.88) 1.35 0.002 
Average 123516 (52.47) 285 (55.02) 1 REF 49425 (52.57) 1529 (54.63) 1 REF 50222 (52.61) 732 (53.74) 1 REF 
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Brisk 97022 (41.21) 159 (30.69) 0.71 0.0006 38695 (41.16) 946 (33.80) 0.80 < 0.0001 39132 (41.00) 509 (37.37) 0.89 0.050 
Grip strength (Kg) 31.31 (10.93) 31.44 (10.39) 1.01 0.79 31.31 (10.97) 27.46 (9.99) 0.69 < 0.0001 31.22 (10.96) 29.99 (10.96) 0.89 < 0.0001 
Prevalent disease at baseline, n (%)             
Longstanding illness 68156 (28.95) 208 (40.15) 1.64 < 0.0001 27777 (29.55) 1211 (43.27) 1.78 < 0.0001 28500 (29.86) 488 (35.83) 1.31 < 0.0001 
Diabetes 10959 (4.66) 48 (9.27) 2.09 < 0.0001 4386 (4.67) 209 (7.47) 1.62 < 0.0001 4510 (4.72) 85 (6.24) 1.34 0.009 
CVD 11229 (4.77) 44 (8.49) 1.85 < 0.0001 4689 (4.99) 199 (7.11) 1.44 < 0.0001 4805 (5.03) 83 (6.09) 1.22 0.08 
Cancer 15841 (6.75) 40 (7.77) 1.16 0.36 6339 (6.76) 245 (8.80) 1.32 < 0.0001 6480 (6.81) 104 (7.66) 1.13 0.22 
Depression 45765 (19.44) 84 (16.22) 0.80 0.06 18180 (19.34) 505 (18.04) 0.92 0.09 18417 (19.29) 268 (19.68) 1.02 0.72 
CKD stages 3-5 291 (0.12) 4 (0.77) 6.22 0.0003 122 (0.13) 6 (0.21) 1.62 0.23 125 (0.13) 3 (0.22) 1.67 0.37 
SLE 274 (0.12) 0 (0.00) 0.00 0.96 115 (0.12) 10 (0.36) 2.77 0.001 123 (0.13) 2 (0.15) 1.14 0.85 
Asthma 27705 (11.77) 71 (13.71) 1.19 0.17 10897 (11.59) 570 (20.36) 1.90 < 0.0001 11250 (11.79) 217 (15.93) 1.41 < 0.0001 
Sleep apnoea 718 (0.30) 4 (0.77) 2.54 0.06 301 (0.32) 16 (0.57) 1.75 0.02 311 (0.33) 6 (0.44) 1.35 0.46 
COPD 535 (0.23) 4 (0.77) 3.40 0.01 220 (0.23) 21 (0.75) 3.03 < 0.0001 231 (0.24) 10 (0.73) 2.96 0.0006 
Bronchitis 2514 (1.07) 9 (1.74) 1.64 0.14 1011 (1.08) 80 (2.86) 2.58 < 0.0001 1061 (1.11) 30 (2.20) 1.98 0.0002 
Pneumonia 2935 (1.25) 11 (2.12) 1.72 0.08 1115 (1.19) 41 (1.46) 1.23 0.18 1140 (1.19) 16 (1.17) 0.98 0.95 
Other respiratory disease 1242 (0.53) 4 (0.77) 1.47 0.45 489 (0.52) 23 (0.82) 1.56 0.03 508 (0.53) 4 (0.29) 0.55 0.23 
Medication at baseline, n (%)             
Statin 36295 (15.42) 117 (22.59) 1.60 < 0.0001 14836 (15.78) 561 (20.04) 1.33 < 0.0001 15161 (15.88) 236 (17.33) 1.11 0.15 
BP medication 37560 (15.96) 135 (26.06) 1.85 < 0.0001 15249 (16.22) 504 (18.01) 1.13 0.01 15504 (16.24) 249 (18.28) 1.15 0.04 
Steroid 876 (0.37) 1 (0.19) 0.52 0.51 334 (0.36) 21 (0.75) 2.05 0.0009 352 (0.37) 3 (0.22) 0.60 0.37 
Biomarker at baseline             
Total cholesterol (mmol/L) 5.62 (4.92-6.34) 5.45 (4.71-6.20) 0.84 < 0.0001 5.63 (4.91-6.35) 5.52 (4.80-6.26) 0.92 < 0.0001 5.63 (4.91-6.34) 5.51 (4.83-6.26) 0.92 0.0010 
HDL cholesterol (mmol/L) 1.40 (1.17-1.67) 1.29 (1.09-1.53) 0.71 < 0.0001 1.39 (1.17-1.67) 1.42 (1.18-1.70) 1.05 0.004 1.40 (1.17-1.67) 1.37 (1.15-1.65) 0.93 0.01 
Cystatin C (mg/L) 0.88 (0.80-0.97) 0.93 (0.83-1.02) 1.35 < 0.0001 0.88 (0.80-0.97) 0.88 (0.79-0.99) 1.05 0.01 0.88 (0.80-0.97) 0.89 (0.80-0.99) 1.08 0.004 
HbA1c (mmol/mol) 35.10 (32.60-37.60) 35.90 (33.40-39.38) 1.26 < 0.0001 35.10 (32.60-37.60) 35.60 (33.10-38.50) 1.16 < 0.0001 35.10 (32.60-37.60) 35.30 (32.80-38.20) 1.08 0.0005 
CRP (mg/L) 1.25 (0.63-2.56) 1.67 (0.87-3.23) 1.26 < 0.0001 1.26 (0.63-2.57) 1.54 (0.78-3.19) 1.16 < 0.0001 1.26 (0.64-2.58) 1.46 (0.71-3.04) 1.08 0.0005 
Rheumatoid factor (IU/ml) 3.16 (3.16-3.16) 3.16 (3.16-3.16) 1.15 < 0.0001 3.16 (3.16-3.16) 3.16 (3.16-3.16) 1.13 < 0.0001 3.16 (3.16-3.16) 3.16 (3.16-3.16) 1.11 < 0.0001 
Red cell distribution width (%) 13.30 (12.90-13.80) 13.34 (12.97-13.94) 1.03 0.50 13.30 (12.89-13.80) 13.39 (12.93-13.91) 1.04 0.03 13.30 (12.89-13.80) 13.30 (12.90-13.80) 1.04 0.07 
White cell count (10^9 cells/Litre) 6.60 (5.61-7.80) 6.82 (5.82-8.20) 1.14 0.0005 6.62 (5.63-7.80) 6.89 (5.83-8.18) 1.11 < 0.0001 6.63 (5.64-7.80) 6.86 (5.75-8.07) 1.02 0.39 
Neutrophil count (10^9 cells/Litre) 4.00 (3.25-4.90) 4.11 (3.30-5.11) 1.15 0.0007 4.00 (3.26-4.91) 4.20 (3.42-5.10) 1.16 < 0.0001 4.01 (3.26-4.92) 4.19 (3.32-5.07) 1.12 < 0.0001 
Lymphocyte count (10^9 cells/Litre) 1.88 (1.52-2.29) 1.90 (1.55-2.40) 1.11 0.01 1.88 (1.52-2.29) 1.92 (1.55-2.39) 1.14 < 0.0001 1.88 (1.52-2.29) 1.90 (1.53-2.36) 1.10 0.0003 
Monocyte count (10^9 cells/Litre) 0.45 (0.36-0.56) 0.48 (0.38-0.58) 1.11 0.01 0.45 (0.37-0.57) 0.45 (0.37-0.57) 1.10 < 0.0001 0.45 (0.37-0.57) 0.46 (0.37-0.58) 1.07 0.01 
Numbers represent number (%) for categorical variables, mean (SD) for gaussian continuous variables, and median (25-75th percentiles) for 
skewed variables 
 *Univariable relative risk ratio per 1 standard deviation for continuous variables and using comparator group for categorical variables. 
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Supplementary table 2. Sensitivity analysis for pneumonia occurring after 2015. 





n=767 RR P RR (95% CI) P RR (95% CI) P 
Mean (SD) Age 66.52 (8.06) 68.44 (7.87) 1.28 < 0.0001 1.18 (1.12, 1.24) < 0.0001 1.10 (1.04, 1.17) 0.001 
Age categories           
<50 23642 (24.57) 96 (15.79) 1  REF - - - - 
50-54 15174 (15.77) 80 (13.16) 1.30 0.09 - - - - 
55-59 17523 (18.21) 128 (21.05) 1.79 < 0.0001 - - - - 
60-64 23142 (24.05) 154 (25.33) 1.63 0.0002 - - - - 
≥65 16725 (17.38) 150 (24.67) 2.20 < 0.0001 - - - - 
Male 45416 (47.21) 204 (33.55) 0.57 < 0.0001 0.56 (0.47, 0.66) < 0.0001 0.72 (0.58, 0.89) 0.003 
Ethnicity           
White 92091 (95.72) 587 (96.55) 1  REF 1 (Reference) - 1 (Reference) - 
Black 906 (0.94) 5 (0.82) 0.87 0.75 0.88 (0.36, 2.13) 0.78 0.72 (0.29, 1.75) 0.47 
South Asian 1600 (1.66) 8 (1.32) 0.79 0.50 0.85 (0.42, 1.71) 0.65 0.66 (0.32, 1.34) 0.25 
Others 1609 (1.67) 8 (1.32) 0.78 0.49 0.82 (0.41, 1.66) 0.59 0.72 (0.36, 1.45) 0.36 
Mean (SD) deprivation index -1.49 (2.90) -1.22 (3.01) 1.09 0.03 1.12 (1.04, 1.22) 0.004 1.07 (0.98, 1.16) 0.11 
Current/former smoker 43642 (45.36) 294 (48.36) 1.13 0.14 0.95 (0.72, 1.25) 0.71 1.07 (0.91, 1.26) 0.43 
Alcohol drinking status           
Never 3696 (3.84) 31 (5.10) 1  REF 1 (Reference) - - - 
Former 3077 (3.20) 26 (4.28) 1.01 0.98 1.28 (0.58, 2.79) 0.54 - - 
Current 89433 (92.96) 551 (90.62) 0.74 0.10 0.66 (0.37, 1.18) 0.16 - - 
Mean (SD) BMI 27.41 (4.56) 28.16 (5.11) 1.16 < 0.0001 1.25 (1.11, 1.41) 0.0002 1.09 (1.01, 1.18) 0.03 
BMI categories         
Underweight 304 (0.32) 2 (0.33) 1.10 0.90 1.43 (0.20, 10.4) 0.73 - - 
Normal 31058 (32.28) 186 (30.59) 1  REF 1 (Reference) - - - 
Overweight 41705 (43.35) 242 (39.80) 0.97 0.75 1.01 (0.72, 1.42) 0.94 - - 
Obese 23139 (24.05) 178 (29.28) 1.28 0.02 1.44 (1.01, 2.05) 0.04 - - 
Mean (SD) Body fat-free mass 53.76 (11.49) 51.26 (11.04) 0.80 < 0.0001 1.42 (1.10, 1.84) 0.008 - - 
Mean (SD) Body fat mass 24.68 (9.21) 26.95 (10.05) 1.24 < 0.0001 1.27 (1.12, 1.44) 0.0002 - - 
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Mean (SD) Body fat percent 31.18 (8.41) 34.01 (8.33) 1.39 < 0.0001 1.34 (1.11, 1.62) 0.002 - - 
Mean (SD) Systolic blood 
pressure 137.56 (18.10) 137.18 (18.02) 0.98 0.61 0.94 (0.81, 1.08) 0.39 - - 
Mean (SD) Diastolic blood 
pressure 82.20 (9.90) 81.48 (9.76) 0.93 0.08 0.90 (0.79, 1.04) 0.16 - - 
Mean (SD) FEV1 2.86 (0.78) 2.56 (0.75) 0.66 < 0.0001 0.70 (0.58, 0.86) 0.0005 0.79 (0.70, 0.89) < 0.0001 
Mean (SD) FVC 3.79 (0.99) 3.43 (0.94) 0.67 < 0.0001 0.72 (0.59, 0.90) 0.003 - - 
Mean (SD) FEV1/FVC 0.76 (0.06) 0.74 (0.07) 0.86 < 0.0001 0.84 (0.74, 0.95) 0.007 - - 
Walking pace           
Slow 50630 (52.63) 324 (53.29) 1.90 < 0.0001 1.91 (1.26, 2.90) 0.002 1.53 (1.18, 2.00) 0.001 
Average 6144 (6.39) 75 (12.34) 1  REF 1 (Reference) - 1 (Reference) - 
Brisk 39432 (40.99) 209 (34.38) 0.83 0.03 0.78 (0.57, 1.06) 0.11 0.96 (0.80, 1.15) 0.65 
Mean (SD) grip strength 31.22 (10.96) 27.84 (10.44) 0.72 < 0.0001 0.85 (0.68, 1.07) 0.16 0.96 (0.76, 1.22) 0.76 
Prevalent disease at baseline         
Longstanding illness 28729 (29.86) 259 (42.60) 1.74 < 0.0001 1.65 (1.25, 2.18) 0.0004 1.40 (1.04, 1.88) 0.03 
Diabetes 4549 (4.73) 46 (7.57) 1.64 0.001 2.06 (1.29, 3.30) 0.002 1.59 (0.98, 2.59) 0.06 
CVD 4842 (5.03) 46 (7.57) 1.54 0.005 1.64 (1.00, 2.70) 0.052 1.35 (0.81, 2.24) 0.25 
Cancer 6525 (6.80) 59 (9.80) 1.48 0.004 1.72 (1.14, 2.60) 0.009 1.72 (1.14, 2.60) 0.01 
Depression 18587 (19.32) 98 (16.12) 0.80 0.047 0.81 (0.56, 1.18) 0.27 0.86 (0.59, 1.25) 0.42 
Asthma 11342 (11.79) 125 (20.56) 1.93 < 0.0001 1.44 (0.99, 2.09) 0.054 1.25 (0.85, 1.82) 0.25 
COPD 238 (0.25) 3 (0.49) 1.99 0.23 - - - - 
Bronchitis 1074 (1.12) 17 (2.80) 2.52 0.0002 2.23 (0.98, 5.06) 0.055 1.77 (0.77, 4.07) 0.18 
Pneumonia 1144 (1.19) 12 (1.97) 1.67 0.08 1.53 (0.57, 4.14) 0.40 1.47 (0.54, 3.99) 0.45 
Other respiratory disease 507 (0.53) 5 (0.82) 1.56 0.32 0.84 (0.12, 6.04) 0.86 0.76 (0.10, 5.52) 0.78 
Medication at baseline         
Statin 15265 (15.87) 132 (21.71) 1.47 < 0.0001 1.08 (0.75, 1.55) 0.69 0.91 (0.62, 1.32) 0.62 
BP medication 15636 (16.25) 117 (19.24) 1.23 0.047 0.96 (0.66, 1.41) 0.85 0.82 (0.55, 1.21) 0.31 
Steroid 352 (0.37) 3 (0.49) 1.35 0.61 1.20 (0.17, 8.63) 0.86 1.03 (0.14, 7.53) 0.97 
Median (IQR) Biomarker at 
baseline         
Total cholesterol 5.62 (4.91-6.34) 5.55 (4.80-6.26) 0.94 0.10 0.94 (0.82, 1.08) 0.40 0.98 (0.85, 1.12) 0.76 
HDL cholesterol 1.39 (1.17-1.67) 1.41 (1.17-1.70) 1.05 0.20 0.88 (0.76, 1.03) 0.11 0.98 (0.84, 1.16) 0.84 
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Cystatin C 0.88 (0.80-0.97) 0.90 (0.80-1.01) 1.17 < 0.0001 1.08 (0.94, 1.24) 0.29 0.96 (0.83, 1.12) 0.59 
HbA1c 35.10 (32.60-37.60) 35.70 (33.38-38.60) 1.18 < 0.0001 1.19 (1.07, 1.33) 0.001 1.11 (0.99, 1.25) 0.07 
CRP 1.27 (0.64-2.59) 1.50 (0.81-3.05) 1.14 < 0.0001 1.11 (1.00, 1.24) 0.04 1.03 (0.91, 1.16) 0.67 
Rheumatoid factor 3.16 (3.16-3.16) 3.16 (3.16-3.16) 1.04 0.22 1.03 (0.91, 1.15) 0.68 1.02 (0.90, 1.15) 0.76 
Red cell distribution width 13.30 (12.89-13.80) 13.37 (12.95-13.91) 1.10 0.01 1.12 (0.99, 1.27) 0.07 1.07 (0.95, 1.22) 0.27 
White cell count 6.63 (5.64-7.80) 6.93 (5.90-8.10) 1.15 0.0002 1.15 (1.01, 1.32) 0.03 1.07 (0.93, 1.23) 0.32 
Neutrophil count 4.01 (3.26-4.92) 4.19 (3.52-5.13) 1.12 0.003 1.11 (0.97, 1.27) 0.12 1.04 (0.91, 1.19) 0.57 
Lymphocyte count 1.88 (1.52-2.29) 1.92 (1.60-2.35) 1.09 0.02 1.07 (0.94, 1.23) 0.28 1.02 (0.89, 1.17) 0.76 
Monocyte count 0.45 (0.37-0.57) 0.46 (0.37-0.58) 1.06 0.13 1.11 (0.97, 1.28) 0.12 1.06 (0.92, 1.21) 0.43 
Variables with associations denoted “-“ are excluded from the model due to non-significance in previous model and /or collinearity with another variable. 
Model 1 adjusts for age, sex, ethnicity, deprivation 
Model 2 adjusted for model 1 plus BMI, FEV1, and walking pace  
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Supplementary table 3. Linearity of continuous variables with COVID-19 and influenza. 
  Covid-19 Pneumonia (after 2016) Influenza (after 2016) 
   χ2 df Pnonlinear χ2 df Pnonlinear χ2 df Pnonlinear 
Age 16.32 2.00 0.0003 2.36 1.99 0.30 1.99 2.00 0.37 
Deprivation index 0.01 0.07 0.15 2.63 2.00 0.27 2.01 2.00 0.37 
BMI 0.85 1.98 0.65 4.93 2.00 0.08 0.00 0.03 0.08 
Body fat-free mass 5.44 1.98 0.06 5.45 1.92 0.06 1.32 2.00 0.52 
Body fat mass 2.74 1.99 0.25 2.30 1.99 0.31 0.96 2.00 0.62 
Body fat percent 0.66 1.97 0.71 1.00 2.00 0.61 0.00 0.02 0.09 
Systolic blood pressure 1.65 2.00 0.44 0.84 1.99 0.65 2.24 2.00 0.33 
Diastolic blood pressure 2.55 1.99 0.28 0.14 1.51 0.86 1.60 1.97 0.44 
FEV1 1.04 1.98 0.59 8.50 1.92 0.01 4.07 1.94 0.12 
FVC 0.00 0.03 0.08 8.95 1.95 0.01 1.42 1.99 0.49 
FEV1/FVC 3.23 1.98 0.20 3.10 1.83 0.19 0.62 2.00 0.73 
Grip strength 7.05 2.00 0.03 2.75 1.93 0.24 0.37 2.00 0.83 
Biomarker at baseline          
Total cholesterol 7.40 1.95 0.02 0.94 1.99 0.62 2.50 1.99 0.28 
HDL cholesterol 0.00 0.03 0.08 2.69 1.94 0.25 1.89 1.98 0.38 
Cystatin C 3.02 1.99 0.22 1.31 1.99 0.52 1.05 1.99 0.59 
HbA1c 6.23 2.00 0.04 3.71 2.00 0.16 4.93 2.00 0.08 
CRP 11.86 1.99 0.003 7.84 1.99 0.02 5.08 2.00 0.08 
Rheumatoid factor 2.22 2.00 0.33 4.24 2.00 0.12 1.70 1.99 0.43 
Red cell distribution width 0.55 1.99 0.76 5.07 2.00 0.08 3.64 1.95 0.16 
White cell count 5.25 2.00 0.07 1.43 2.00 0.49 0.00 0.03 0.08 
Neutrophil count 3.51 1.97 0.17 1.33 2.00 0.51 2.44 1.94 0.28 
Lymphocyte count 2.85 1.91 0.23 1.13 2.00 0.57 13.41 2.00 0.001 
Monocyte count 0.01 0.04 0.11 1.14 1.76 0.50 9.36 1.91 0.008 
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Supplementary table 4. Association of risk factors for COVID-19 and pneumonia in UK Biobank with 
body fat percent replacing BMI in Model 2 
  COVID-19 Pneumonia (after 2016) 
  RR (95% CI) P RR (95% CI) P 
Age 1.02 (0.95, 1.09) 0.63 1.11 (1.00, 1.23) 0.048 
Male 2.72 (1.89, 3.93) < 0.0001 1.05 (0.67, 1.63) 0.84 
Ethnicity     
White 1 (Reference)  1 (Reference)  
Black 2.01 (1.13, 3.55) 0.02 1.22 (0.38, 3.94) 0.74 
South Asian 1.60 (0.87, 2.93) 0.13 0.63 (0.19, 2.03) 0.44 
Others 1.67 (0.98, 2.86) 0.06 0.51 (0.12, 2.12) 0.36 
Deprivation index 1.18 (1.07, 1.29) 0.0009 1.04 (0.90, 1.20) 0.57 
Current/former smoker 1.38 (1.12, 1.69) 0.002 0.89 (0.67, 1.18) 0.42 
Body fat percent 1.42 (1.23, 1.65) < 0.0001 1.20 (0.98, 1.46) 0.08 
FEV1 0.84 (0.73, 0.97) 0.02 0.75 (0.61, 0.92) 0.005 
Walking pace     
Slow 1.61 (1.18, 2.18) 0.002 1.66 (1.08, 2.55) 0.02 
Average 1 (Reference)  1 (Reference)  
Brisk 0.95 (0.75, 1.19) 0.64 0.87 (0.63, 1.20) 0.39 
grip strength 0.97 (0.83, 1.13) 0.71 0.98 (0.78, 1.24) 0.88 
Prevalent disease at baseline     
Longstanding illness 1.16 (0.93, 1.44) 0.18 1.40 (1.04, 1.89) 0.02 
Diabetes 1.30 (0.91, 1.85) 0.15 1.65 (1.02, 2.68) 0.04 
CVD 1.22 (0.84, 1.76) 0.29 1.35 (0.81, 2.25) 0.25 
Cancer 1.20 (0.83, 1.74) 0.33 1.72 (1.13, 2.60) 0.01 
Depression 1.01 (0.77, 1.32) 0.94 0.86 (0.59, 1.25) 0.42 
Asthma 1.05 (0.78, 1.41) 0.76 1.25 (0.86, 1.83) 0.25 
COPD 1.77 (0.55, 5.67) 0.34 - - 
Bronchitis 1.24 (0.60, 2.55) 0.56 1.75 (0.76, 4.03) 0.19 
Pneumonia 1.50 (0.74, 3.06) 0.26 1.46 (0.54, 3.98) 0.46 
Other respiratory disease 1.20 (0.38, 3.79) 0.76 0.75 (0.10, 5.48) 0.78 
Medication at baseline     
Statin 1.25 (0.98, 1.61) 0.08 0.92 (0.63, 1.34) 0.67 
BP medication 1.35 (1.05, 1.72) 0.02 0.83 (0.56, 1.23) 0.35 
Steroid 0.52 (0.07, 3.82) 0.52 1.03 (0.14, 7.51) 0.98 
Biomarker     
Total cholesterol 0.92 (0.83, 1.01) 0.09 0.97 (0.85, 1.11) 0.67 
HDL cholesterol 0.82 (0.72, 0.93) 0.002 0.97 (0.83, 1.14) 0.70 
Cystatin C 1.14 (1.03, 1.26) 0.009 0.97 (0.84, 1.13) 0.72 
HbA1c 1.15 (1.06, 1.24) 0.0003 1.13 (1.00, 1.26) 0.04 
CRP 1.04 (0.95, 1.13) 0.38 1.04 (0.92, 1.17) 0.56 
Rheumatoid factor 1.01 (0.92, 1.11) 0.85 1.02 (0.90, 1.15) 0.77 
Red cell distribution width 1.04 (0.95, 1.14) 0.43 1.08 (0.95, 1.23) 0.23 
White cell count 1.04 (0.94, 1.15) 0.43 1.08 (0.94, 1.23) 0.29 
Neutrophil count 1.03 (0.93, 1.13) 0.62 1.04 (0.91, 1.20) 0.54 
Lymphocyte count 1.03 (0.94, 1.14) 0.51 1.03 (0.90, 1.17) 0.71 
Monocyte count 1.01 (0.92, 1.12) 0.77 1.06 (0.92, 1.22) 0.41 
Data presented as risk ratios and their 95% CI. continuous exposures were standardised and 
presented as 1-standard deviation (SD) increment.  
Adjusted for age, sex, ethnicity, deprivation, body fat %, FEV1, and walking pace  
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